Low metformin dose and its therapeutic serum concentration in prediabetes

Abstract This prospective study aimed to analyze whether the patients with pre-diabetes (pre-DM) reach the TC (therapeutic concentration) of the metformin during repeated, low, constant drug dose. The guidelines do not recommend any metformin dose for this group of patients. Based on the previous st...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Edyta Sutkowska, Paulina Fortuna, Jerzy Wisniewski, Karolina Sutkowska, Pawel Hodurek, Andrzej Gamian, Bernadetta Kaluza
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/29cd40c9fc5d44d38efb247446bf924a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29cd40c9fc5d44d38efb247446bf924a
record_format	dspace
spelling	oai:doaj.org-article:29cd40c9fc5d44d38efb247446bf924a2021-12-02T15:02:57ZLow metformin dose and its therapeutic serum concentration in prediabetes10.1038/s41598-021-91174-72045-2322https://doaj.org/article/29cd40c9fc5d44d38efb247446bf924a2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91174-7https://doaj.org/toc/2045-2322Abstract This prospective study aimed to analyze whether the patients with pre-diabetes (pre-DM) reach the TC (therapeutic concentration) of the metformin during repeated, low, constant drug dose. The guidelines do not recommend any metformin dose for this group of patients. Based on the previous study after a dose of 1700 mg/day the patients seem to reach the therapeutic drug concentration, which guarantees the glycemic effect. Twenty patients with new-diagnosed pre-DM were treated with a 1500 mg/day regimen of the metformin for 15 weeks. The serum concentration of the drug was assessed by liquid chromatography-mass spectrometry technique at 6 and 15 week of the treatment. The correlation of the serum metformin concentration with BMI (body mass index) and patients’ weight was also performed. The mean metformin concentration was: 4.65 μmol/L (± 2.41) and 5.41 μmol/L (± 3.44) (p = 0.27) after 6 and 15 weeks of the treatment respectively. There was a positive correlation between the serum concentration of the metformin and body weight (but not BMI) in the 15th week of the therapy (p = 0.04)- the higher body weight the higher concentration of the metformin. Patients with pre-diabetes can be successfully treated with a low dose of metformin, to reach the drug’s therapeutic concentration. Body weight can impact the metformin serum concentration during long-term treatment what should be taken into consideration when choosing the dose because of its pleiotropic effect e.g. on the cardiovascular system via reduction of the oxidative stress and would be not connected with the drug’s hypoglycemic effect. ClinicalTrials.gov number: NCT03398356; date of first registration: 01/07/2018.Edyta SutkowskaPaulina FortunaJerzy WisniewskiKarolina SutkowskaPawel HodurekAndrzej GamianBernadetta KaluzaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Edyta Sutkowska Paulina Fortuna Jerzy Wisniewski Karolina Sutkowska Pawel Hodurek Andrzej Gamian Bernadetta Kaluza Low metformin dose and its therapeutic serum concentration in prediabetes
description	Abstract This prospective study aimed to analyze whether the patients with pre-diabetes (pre-DM) reach the TC (therapeutic concentration) of the metformin during repeated, low, constant drug dose. The guidelines do not recommend any metformin dose for this group of patients. Based on the previous study after a dose of 1700 mg/day the patients seem to reach the therapeutic drug concentration, which guarantees the glycemic effect. Twenty patients with new-diagnosed pre-DM were treated with a 1500 mg/day regimen of the metformin for 15 weeks. The serum concentration of the drug was assessed by liquid chromatography-mass spectrometry technique at 6 and 15 week of the treatment. The correlation of the serum metformin concentration with BMI (body mass index) and patients’ weight was also performed. The mean metformin concentration was: 4.65 μmol/L (± 2.41) and 5.41 μmol/L (± 3.44) (p = 0.27) after 6 and 15 weeks of the treatment respectively. There was a positive correlation between the serum concentration of the metformin and body weight (but not BMI) in the 15th week of the therapy (p = 0.04)- the higher body weight the higher concentration of the metformin. Patients with pre-diabetes can be successfully treated with a low dose of metformin, to reach the drug’s therapeutic concentration. Body weight can impact the metformin serum concentration during long-term treatment what should be taken into consideration when choosing the dose because of its pleiotropic effect e.g. on the cardiovascular system via reduction of the oxidative stress and would be not connected with the drug’s hypoglycemic effect. ClinicalTrials.gov number: NCT03398356; date of first registration: 01/07/2018.
format	article
author	Edyta Sutkowska Paulina Fortuna Jerzy Wisniewski Karolina Sutkowska Pawel Hodurek Andrzej Gamian Bernadetta Kaluza
author_facet	Edyta Sutkowska Paulina Fortuna Jerzy Wisniewski Karolina Sutkowska Pawel Hodurek Andrzej Gamian Bernadetta Kaluza
author_sort	Edyta Sutkowska
title	Low metformin dose and its therapeutic serum concentration in prediabetes
title_short	Low metformin dose and its therapeutic serum concentration in prediabetes
title_full	Low metformin dose and its therapeutic serum concentration in prediabetes
title_fullStr	Low metformin dose and its therapeutic serum concentration in prediabetes
title_full_unstemmed	Low metformin dose and its therapeutic serum concentration in prediabetes
title_sort	low metformin dose and its therapeutic serum concentration in prediabetes
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/29cd40c9fc5d44d38efb247446bf924a
work_keys_str_mv	AT edytasutkowska lowmetformindoseanditstherapeuticserumconcentrationinprediabetes AT paulinafortuna lowmetformindoseanditstherapeuticserumconcentrationinprediabetes AT jerzywisniewski lowmetformindoseanditstherapeuticserumconcentrationinprediabetes AT karolinasutkowska lowmetformindoseanditstherapeuticserumconcentrationinprediabetes AT pawelhodurek lowmetformindoseanditstherapeuticserumconcentrationinprediabetes AT andrzejgamian lowmetformindoseanditstherapeuticserumconcentrationinprediabetes AT bernadettakaluza lowmetformindoseanditstherapeuticserumconcentrationinprediabetes
_version_	1718389067065851904

Low metformin dose and its therapeutic serum concentration in prediabetes

Ejemplares similares